Document Detail

Treatment of endometriosis with transvaginal ultrasound-guided drainage under GnRH analogues and recombinant interleukin-2 left in the cysts.
MedLine Citation:
PMID:  16244488     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: To analyze the therapeutic results of one dose of 3 million IU of recombinant interleukin-2 (rIL-2) left intracyst (group I) versus two doses with a 1-month interval (group II) after transvaginal ultrasound (US)-guided drainage of endometriomas under the effect of GnRH analogues. METHODS: Prospective and randomized clinical trial (helped by a random number table) at a University Hospital. Twenty-four consecutive patients with endometriomas initially sent to us for laparotomy and conservative surgery for endometriosis were included. INTERVENTIONS: Treatment with GnRH analogues every 28 days, 3 doses. Under their effect, one or two transvaginal US-guided punctures were performed in order to aspirate the endometriomas, and 3 million IU of rIL-2 were left in the aspirated cysts each time. MAIN OUTCOME MEASURES: Clinical results: two menstruations after GnRH analogues. Other secondary outcome measures were: the time until recurrence of cysts, symptoms and CA-125 >35 U/ml, and the need for further medical or surgical treatment. RESULTS: They were moderate or good in >50% of cases with one drainage and one dose of 3 million IU of rIL-2 intracyst, but were better with a second drainage and two doses of rIL-2 (25 vs. 58.3% 'good results'). There were fewer recurrences and the interval before recurrence was longer after two doses but differences were not significant. Six patients from group I (50%) and 3 from group II (25%) needed laparotomy and conservative surgery at 17.5 +/- 8.7 months (total time of follow-up = 33 +/- 8.8 months). CONCLUSIONS: Treatment of endometriomas with transvaginal US-guided drainage and rIL-2 left in the cysts under endometrial suppressive therapy with GnRH analogues has beneficial effects, improving clinical manifestations and avoiding some surgical therapies. The use of a higher dose of rIL-2 does not produce better results, whereas drainage + rIL-2 twice does.
Pedro Acién; Gloria Pérez-Albert; Francisco J Quereda; Marisa Sánchez-Ferrer; Ana García-Almela; Irene Velasco
Related Documents :
9352418 - Autoimmune progesterone dermatitis: effective prophylactic treatment with danazol.
8692508 - Natural cytotoxicity and gnrh agonist administration in advanced endometriosis: positiv...
8557138 - Danazol versus a gonadotropin-releasing hormone agonist as preoperative preparation for...
8725758 - Endometrial resection vs. abdominal hysterectomy for menorrhagia. correlated sample ana...
24186878 - Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-c...
11080238 - Late onset heterozygous ornithine transcarbamylase deficiency mimicking complex partial...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2005-10-21
Journal Detail:
Title:  Gynecologic and obstetric investigation     Volume:  60     ISSN:  0378-7346     ISO Abbreviation:  Gynecol. Obstet. Invest.     Publication Date:  2005  
Date Detail:
Created Date:  2005-10-31     Completed Date:  2006-01-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7900587     Medline TA:  Gynecol Obstet Invest     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  224-31     Citation Subset:  IM    
Copyright Information:
Copyright 2005 S. Karger AG, Basel.
Service of Obstetrics and Gynecology, San Juan University Hospital and Department of Gynecology, School of Medicine, Miguel Hernandez University, Campus of San Juan, Alicante, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Topical
Drainage / methods
Endometriosis / drug therapy,  pathology,  therapy*,  ultrasonography
Gonadotropin-Releasing Hormone / agonists
Interleukin-2 / administration & dosage,  therapeutic use
Recombinant Proteins / therapeutic use
Treatment Outcome
Triptorelin / therapeutic use*
Reg. No./Substance:
0/Interleukin-2; 0/Recombinant Proteins; 33515-09-2/Gonadotropin-Releasing Hormone; 57773-63-4/Triptorelin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intravenous TPA for very old stroke patients.
Next Document:  A rapidly growing paraurethral myoma with profuse bleeding from a mucosal vessel: report of a case.